Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.

Albina NowakFelix BeuschleinVisnuka SivasubramaniamDavid KasperDavid G Warnock

Published in: Journal of medical genetics (2021)

Lyso-Gb3 is a significant risk factor associated with important clinical events. Whether treatment-related amelioration of Lyso-Gb3 levels will be associated with improved long-term outcome needs to be established in prospective intervention trials.

Keyphrases

risk factors
randomized controlled trial
replacement therapy
emergency department
combination therapy
adverse drug
drug induced